Skip to content

ArriVent BioPharma, Inc.

AVBP

CIK 0001868279

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
−$174.08M
−106.6% YoY Q1 May 2026
EPS Diluted (TTM)
−$4.59
−68.8% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
—
Q1 May 2026
Cash
$62.1M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
46.57M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings